Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday

Key Points

• Q1 2026 results are due before market open on May 12 with analysts expecting EPS of ($0.08); a conference call is scheduled for May 14 and the company last reported ($0.09) EPS, beating estimates by $0.01.
• Director Gregg Williams made a large insider purchase, acquiring 1,587,301 shares at about $1.26 each (~$2.0M) on April 15, raising his holdings to 32,944,484 shares and contributing to insiders owning 46.40% of the stock.
• Stock and analyst snapshot: VANI traded at $1.29 (down 4.1%), has a market cap of ~$110.8M and a 12‑month range of $0.92–$1.92, and carries a consensus "Hold" rating with a $3.50 target amid mixed analyst views.

Vivani Medical (NASDAQ:VANI - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Vivani Medical (NASDAQ:VANI - Get Free Report) last released its earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Vivani Medical Stock Down 4.1%

Shares of VANI stock traded down $0.06 during trading hours on Tuesday, hitting $1.29. 99,770 shares of the company's stock traded hands, compared to its average volume of 305,891. The stock's fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $1.32. Vivani Medical has a 12-month low of $0.92 and a 12-month high of $1.92. The stock has a market cap of $110.82 million, a price-to-earnings ratio of -2.99 and a beta of 2.35.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vivani Medical in a report on Friday, January 9th. HC Wainwright lowered their price target on Vivani Medical from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vivani Medical currently has a consensus rating of "Hold" and a consensus target price of $3.50.

Insiders Place Their Bets

In other news, Director Gregg Williams acquired 1,587,301 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director directly owned 32,944,484 shares in the company, valued at approximately $41,510,049.84. The trade was a 5.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 46.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vivani Medical

A number of hedge funds have recently bought and sold shares of VANI. Citadel Advisors LLC purchased a new position in Vivani Medical in the 3rd quarter worth about $26,000. Susquehanna International Group LLP raised its position in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after buying an additional 16,200 shares during the last quarter. Jane Street Group LLC purchased a new position in Vivani Medical in the 4th quarter worth about $60,000. Renaissance Technologies LLC raised its position in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company's stock worth $121,000 after buying an additional 53,127 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Vivani Medical in the 4th quarter worth about $174,000. Hedge funds and other institutional investors own 6.78% of the company's stock.

About Vivani Medical

Vivani Medical Solutions, Inc NASDAQ: VANI is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.